 PALO ALTO, Calif., March 28, 2022 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO BridgeBio or the Company, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that updated data from its ongoing Phase 2 open-label extension OLE study of acoramidis AG10 in patients with symptomatic transthyretin TTR amyloid cardiomyopathy ATTR-CM will be featured in an oral presentation at the American College of Cardiology ACC Annual Scientific Session Expo, taking place in Washington, D.C. on April 2 4, 2022. 